EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Epstein–Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations

Danielle N Burner iD, Giselle Y López iD, Justin T Low, Micah A Luftig iD

Viruses · 22.04.2026 · 18 (5) · 485

DOI: 10.3390/v18050485 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Viruses, online erschienen am 22.04.2026. Verfasst von Danielle N Burner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Mycophenolic Acid, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Central Nervous System Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein–Barr virus (EBV)-positive primary central nervous system lymphoma (PCNSL) is a rare entity typically associated with profound immunosuppression, most commonly in transplant recipients or individuals with HIV. We report a case of EBV-positive PCNSL arising in a 75-year-old male with myasthenia gravis receiving chronic mycophenolate mofetil (MMF) therapy outside the transplant setting. The patient presented with progressive neurological deficits, and brain magnetic resonance imaging demonstrated multiple enhancing lesions. Stereotactic biopsy revealed diffuse large B-cell lymphoma of non–germinal center subtype with immunoblastic features and EBV-encoded RNA (EBER) positivity, confirming EBV-positive PCNSL. MMF was discontinued, and the patient was treated with rituximab and high-dose methotrexate, resulting in stable disease. This case highlights that prolonged MMF therapy may confer sufficient immunosuppression to permit EBV-driven lymphoproliferative disease even in non-transplant patients. Early recognition, withdrawal of immunosuppression, and initiation of methotrexate-based chemotherapy can lead to favorable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidEpstein-Barr Virus InfectionsHerpesvirus 4, HumanCentral Nervous System NeoplasmsImmunosuppressive AgentsLymphomaHumansMaleAgedMethotrexateRituximabMagnetic Resonance Imaging

Stichwörter der Autor:innen

Epstein–Barr virusdiffuse large B-cell lymphomamycophenolate mofetilprimary central nervous system lymphoma

Substanzen

Mycophenolic AcidImmunosuppressive AgentsMethotrexateRituximab

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Department of Neurosurgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

ORCID-Profile: Danielle N Burner, Giselle Y López, Micah A Luftig

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Burner, D. N., López, G. Y., Low, J. T., & Luftig, M. A. (2026). Epstein–Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations. Viruses, 18(5), 485. https://doi.org/10.3390/v18050485

Vancouver

Burner DN, López GY, Low JT, Luftig MA. Epstein–Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations. Viruses. 2026;18(5):485. doi:10.3390/v18050485

BibTeX
@article{Burner2026,
  author = {Burner, Danielle N and López, Giselle Y and Low, Justin T and Luftig, Micah A},
  title = {Epstein–Barr Virus-Positive Primary CNS Lymphoma in a Patient Receiving Mycophenolate Mofetil: Diagnostic and Therapeutic Considerations},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {485},
  doi = {10.3390/v18050485}
}
Kostenlos starten →